|
Expression of multiple cancer/testis genes in 32 breast cancer tumor samples
|
Shamseddin Yousef Amoli1   , Leyla Kokabi2 , Alireza Kord Afshari3 , Rezvan Esmaeili4 , Pantea Izadi5 , Mehrdad Norouzniyai6 , Keyvan Majidzadeh Ardabili7 , Morteza Karimipour 8 |
1- MSc of Genetics, Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran, Department of Biology, Faculty of Basic Sciences, Islamic Azad University, Science and Research Campus
2- PhD Candidate of Medical Biotechnology, Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
3- MSc Student of Biology, Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
4- PhD Candidate of Molecular Genetics, Research Group of Cancer Genetics, Breast Cancer Research Center, Jahad Daneshgahi, Tehran, Iran
5- PhD of Medical Genetics, Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
6- Department of Medical Genetics, Faculty of Medicine, Tarbiat Modarres University, Tehran, Iran
7- Research Group of Cancer Genetics, Breast Cancer Research Center, Jahad Daneshgahi, Tehran, Iran
8- Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran , mortezakarimi@yahoo.com |
|
|
Abstract: (10714 Views) |
Background: cancer/testis genes (CT-genes) are a family gene which only express in normal testis tissue some of them are randomly expressed in some types of cancers. The aim of this study was to evaluate the frequency of expression of CT-genes in the patients with breast cancer.
Materials and Methods: Thirty two breast cancer tissue samples were prepared. Expression of NY-ESO-1 1a, NY-ESO-1 1b, SCP1, SSX-2 and MAGE-3 genes, as well as GAPDH (internal control), were studied by multiplex RT-PCR method.
Results: Three (9%) of 32 tumor samples expressed mRNA of NY-ESO-1 1a, while six (19%) of 32 tumor samples expressed mRNA of NY-ESO-1 1b. Seven (22%) and two (6%) of 32 tumor samples expressed mRNA of SCP1 and mRNA of MAGE3, rtepectively. Overall, Thirteen (41%) samples expressed one of the studied genes.
Conclusion: NY-ESO-1 and SCP1 genes had the highest frequency of expression of mRNA. It is suggested that more number of breast cancer tumor samples should be examined to evaluate expression of CT-genes. SCP1 and NY-ESO-1 proteins may promote future breast cancer immunotherapy. |
|
| Keywords: Breast cancer, RT-PCR, Immunotherapy, Cancer/testis genes expression, Tumor marker |
|
|
Full-Text [PDF 208 kb]
(2768 Downloads)
|
Semi-pilot: Experimental |
Subject:
Genetic
Received: 2013/09/22 | Published: 2013/09/15
|
|
|
|
|
|
